Carnegie Investment Counsel’s Pacific Biosciences PACB Stock Holding History

Carnegie Investment Counsel’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,250	Closed	-$63K	–	489
2022 Q2	$63K	Sell	14,250 -21,500	-60%	-$131K	﹤0.01%	464
2022 Q1	$325K	Sell	35,750 -4,922	-12%	-$56.7K	0.01%	402
2021 Q4	$832K	Sell	40,672 -3,300	-8%	-$79.6K	0.03%	289
2021 Q3	$1.12M	Buy	43,972 +1,950	+5%	+$57.8K	0.04%	234
2021 Q2	$1.47M	Buy	42,022 +6,600	+19%	+$192K	0.06%	221
2021 Q1	$1.18M	Buy	35,422 +6,122	+21%	+$214K	0.05%	232
2020 Q4	$760K	Buy	+29,300	New	+$498K	0.03%	250

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carnegie Investment Counsel's PACB Position: Q3 2022 in Review

Carnegie Investment Counsel sold out of Pacific Biosciences (PACB) in Q3 2022, closing a stake of 14,250 shares — an estimated $63K sold.

Carnegie Investment Counsel first reported a position in PACB in Q4 2020 and held it in 7 quarters. The position peaked at $1.47M in Q2 2021. 227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

Carnegie Investment Counsel reported no remaining Pacific Biosciences position as of Q3 2022 after selling out during the quarter.
Carnegie Investment Counsel sold 14,250 Pacific Biosciences shares in Q3 2022, an estimated $63K.
Carnegie Investment Counsel first reported a position in Pacific Biosciences in Q4 2020 and held it in 7 quarters.
Carnegie Investment Counsel's Pacific Biosciences position peaked at $1.47M in Q2 2021.
227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Carnegie Investment Counsel's 13F filing for Q3 2022, filed 14 Oct 2022.